Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute (DFCI) have signed a collaboration and licensing agreement to identify new oncology targets for the development of new therapeutic agents directed at such targets and related biomarkers.
Subscribe to our email newsletter
As per the terms of the agreement, Sanofi-aventis will have access to Belfer’s cancer target identification and validation platform, and translational medicine capabilities.
Belfer has licensed Sanofi-aventis an option to manufacture, develop and commercialise compounds directed at the targets identified and validated under the research collaboration.
Sanofi-aventis is expected to pay a sum of $33m as an upfront payment and research funding for a minimum of three years.
Dana Farber will also be entitled to preclinical, clinical, and commercial milestone payments and royalties on sales of the commercialised products.